

Status: Currently Official on 16-Feb-2025
 Official Date: Official Prior to 2013
 Document Type: USP Monographs
 DocId: GUID-EE8A54B2-836C-4F25-97F2-C32A1B14777F_1_en-US
 DOI: https://doi.org/10.31003/USPNF_M78757_01_01
 DOI Ref: fkb6p

© 2025 USPC
 Do not distribute

Sulfacetamide Sodium Topical Suspension

DEFINITION

Sulfacetamide Sodium Topical Suspension contains NLT 90.0% and NMT 110.0% of the labeled amount of sulfacetamide sodium ($C_8H_9N_2NaO_3S$).

IDENTIFICATION

- **A.** The retention time of the sulfacetamide peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

ASSAY

• PROCEDURE

Mobile phase: Methanol, glacial acetic acid, and water (125:3:875)

Internal standard solution: 5 mg/mL of sulfathiazole sodium

Standard stock solution: 0.25 mg/mL of [USP Sulfacetamide Sodium RS](#) and 0.1 mg/mL of *p*-hydroxybenzoic acid prepared as follows.

Transfer 25 mg of [USP Sulfacetamide Sodium RS](#) and 10 mg of *p*-hydroxybenzoic acid to a 100-mL volumetric flask. Dissolve in water, add 5 mL of the *Internal standard solution*, and dilute with water to volume.

Standard solution: 0.02 mg/mL of [USP Sulfacetamide Sodium RS](#) and 8 µg/mL of *p*-hydroxybenzoic acid in water from the *Standard stock solution*

Sample stock solution: Transfer 250 mg of Topical Suspension to a 125-mL conical flask, add 5 mL of the *Internal standard solution*, and dilute with 95 mL of water.

Sample solution: 2 mL of the *Sample stock solution* diluted with water to 25 mL. Centrifuge, and use the clear supernatant.

Chromatographic system

(See [Chromatography \(621\), System Suitability](#).)

Mode: LC

Detector: UV 254 nm

Column: 3.9-mm × 30-cm; packing L1

Flow rate: 2 mL/min

Injection volume: 20 µL

System suitability

Sample: *Standard solution*

[NOTE—The relative retention times for sulfanilamide, sulfacetamide, sulfathiazole, and *p*-hydroxybenzoic acid are about 0.2, 0.5, 1.0, and 1.2, respectively.]

Suitability requirements

Resolution: NLT 2.0 between sulfathiazole and *p*-hydroxybenzoic acid

Tailing factor: NMT 2

Relative standard deviation: NMT 2.0%

Analysis

Samples: *Standard solution* and *Sample solution*

Calculate the percentage of the labeled amount of anhydrous sulfacetamide sodium ($C_8H_9N_2NaO_3S$) in the portion of Topical Suspension taken:

$$\text{Result} = (R_U/R_S) \times (C_S/C_U) \times 100$$

R_U = peak area ratio of sulfacetamide to sulfathiazole from the *Sample solution*

R_S = peak area ratio of sulfacetamide to sulfathiazole from the *Standard solution*

C_S = concentration of [USP Sulfacetamide Sodium RS](#) in the *Standard solution* (mg/mL)

C_U = nominal concentration of sulfacetamide sodium in the *Sample solution* (mg/mL)

Acceptance criteria: 90.0%–110.0%

PERFORMANCE TESTS

- [MINIMUM FILL \(755\)](#): Meets the requirements

SPECIFIC TESTS

- [MICROBIAL ENUMERATION TESTS \(61\)](#) and [TESTS FOR SPECIFIED MICROORGANISMS \(62\)](#): The total aerobic microbial count does not exceed 10^2 cfu/mL, and the total combined molds and yeasts count does not exceed 50 cfu/mL. It meets the requirements of the test for *Pseudomonas aeruginosa*.
- [pH \(791\)](#): 6.5–7.5

ADDITIONAL REQUIREMENTS

- **PACKAGING AND STORAGE:** Preserve in well-closed containers, at controlled room temperature.
- [USP REFERENCE STANDARDS \(11\)](#).
[USP Sulfacetamide Sodium RS](#)

Auxiliary Information - Please [check for your question in the FAQs](#) before contacting USP.

| Topic/Question | Contact | Expert Committee |
|---|---|---------------------------|
| SULFACETAMIDE SODIUM TOPICAL SUSPENSION | Documentary Standards Support | SM12020 Small Molecules 1 |
| REFERENCE STANDARD SUPPORT | RS Technical Services RSTECH@usp.org | SM12020 Small Molecules 1 |

Chromatographic Database Information: [Chromatographic Database](#)

Most Recently Appeared In:

Pharmacopeial Forum: Volume No. Information currently unavailable

Current DocID: GUID-EE8A54B2-836C-4F25-97F2-C32A1B14777F_1_en-US

DOI: https://doi.org/10.31003/USPNF_M78757_01_01

DOI ref: [fkb6p](#)